Clinical Trials

Phase 2 Not yet recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

19 enrolled

Phase NA Active not recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT06087718 2025-08-14

Feasibility of the Maastro Applicator in Rectal Cancer

10 enrolled

Pathologic Complete Response, Radiation Injuries, Rectal Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Not yet recruiting

600 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT05000697 2024-11-27

CCHOWW

Phase NA Recruiting

216 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04435197 2024-07-03

PALACE-2

Phase 2 Completed

143 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT03125343 2023-11-07

WoW

Phase NA Recruiting

400 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04743102 2023-02-21

BIOPSY

Phase NA Recruiting

260 enrolled

Pathologic Complete Response, Neoplasm Metastasis, Rectal Neoplasms

NCT02233374 2022-10-28

PRISM

Phase NA Completed

27 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04278274 2022-10-26

MR-AI-pCR

205 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05534841 2022-09-10

Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer

99 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04939103 2022-09-01

TRUS-FNA For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer

63 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT01648894 2022-07-25

GRECCAR6

Phase 3 Completed

265 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04917263 2021-06-08

IMMUNOREACT2

544 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04271657 2021-05-06

RPAI-pCR

100 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT03474341 2020-11-16

PRIDE

200 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms

NCT03426397 2020-07-29

"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer

Recruiting

220 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04273477 2020-02-18

MRAI-pCR

100 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT04006041 2019-12-26

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Phase 2 Unknown

44 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Phase 2/3 Completed

716 enrolled

Pathologic Complete Response, Stomach Neoplasms

NCT01863862 2019-03-29

Organ Preservation in Elderly Patients With Rectal Cancer

Phase NA Unknown

90 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT03601689 2018-07-26

Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma

84 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT02353858 2018-02-13

HT01

Phase 2 Completed

78 enrolled